Vivakor, Inc. quarterly report, Q2 FY2010

Vivakor, Inc. 10-Q Summary

Business Context and Reporting Period

This is a Quarterly Report (Form 10-Q) for Vivakor, Inc., a trans-disciplinary biomedical company focused on the discovery, development, and commercialization of medical devices and pharmaceuticals. The report covers the quarterly period ended June 30, 2010. The Company is classified as a "smaller reporting company" and a "shell company" status is denied. As of August 13, 2010, there were 84,925,598 shares of Common Stock outstanding.

Key Financial Metrics

Metric Six Months Ended June 30, 2010 Six Months Ended June 30, 2009
Total Revenues $186,969 $94,987
Gross Profit $79,110 $79,496
Net Loss (Consolidated) $(1,245,986) $(815,717)
Net Loss Attributable to Vivakor $(1,186,722) $(805,735)
Cash and Cash Equivalents (End of Period) $756 $51,578
Net Cash Used in Operating Activities $(343,390) $(86,091)
Total Current Liabilities $1,669,873 $2,216,301
Convertible Notes Payable $78,545 $0

Liquidity Note: The Company reported only $756 in cash and cash equivalents as of June 30, 2010, down from $187,646 at year-end 2009. Current liabilities significantly exceed current assets.

Material Changes vs. Prior Period

  • Revenue Composition: Revenue increased primarily due to license fees ($51,319) and product sales ($135,650) from a new agreement with Regeneca International, Inc. Conversely, grant revenue, which contributed $74,700 in the prior year period, was $0 in the current period.
  • Operating Expenses: Total operating expenses increased to $1,399,162 from $874,495. General and Administrative (G&A) expenses surged to $881,142 from $291,433, driven by increased executive compensation (full-time vs. part-time in 2009) and higher consulting fees for strategy and legal reporting.
  • Debt Structure: The Company issued $167,500 in convertible notes during the period. A significant $510,839 note payable related to the HealthAmerica acquisition was converted into 12.77 million shares of common stock in May 2010, eliminating that specific liability.
  • Asset Changes: Cash decreased by $186,890. The Company distributed its investment in Regeneca International, Inc. ($307,915) to shareholders as a dividend in April 2010.

Outlook, Risks, and Management Commentary

  • Going Concern: Management explicitly states that the Company does not have sufficient cash to fund operations for the next twelve months. The ability to continue as a going concern is dependent on obtaining additional financing through debt, equity, or strategic arrangements. There is no assurance such capital will be available.
  • Capital Formation: The Company is in the midst of a capital formation activity (commenced August 2009). As of June 30, 2010, it had received $319,714 in net cash proceeds and held $1,036,063 in notes receivable from investors, which are accruing interest on a month-to-month basis with no assurance of collection.
  • Product Pipeline: The Company is developing products in molecular medicine, electro-optics (e.g., VivaSight), biological handling (VivaThermic), and nutraceuticals (VivaBoost). Commercialization relies heavily on licensing or partnerships.
  • Risks: Key risks include the inability to raise capital, the failure of the Regeneca distribution agreement to meet sales targets, and the potential dilution of existing shareholders from future equity issuances or convertible note conversions.

Investor Verification Checklist

  • Cash Runway: Verify the immediate liquidity status given the $756 cash balance and the "Going Concern" warning.
  • Notes Receivable Collectability: Assess the likelihood of collecting the $1.036 million in notes receivable from the capital formation activity, which are currently accruing interest.
  • Convertible Note Dilution: Review the terms of the new convertible notes (issued Feb-May 2010) which have anti-dilution provisions and significant conversion liabilities ($144,612 fair value).
  • Regeneca Agreement: Confirm the status of the $5 million purchase commitment from Regeneca International and whether milestone sales targets are being met.
  • Related Party Transactions: Scrutinize the significant related party loans, advances, and the conversion of debt to equity involving stockholders and officers.
Disclaimer:
This AI-generated summary by MetaQuotes is based on SEC filings and may contain errors. Verify important details against the original SEC filings.